Synthesis, Characterization, and Preclinical Evaluation of New Thiazolidin-4-ones Substituted with p-Chlorophenoxy Acetic Acid and Clofibric Acid against Insulin Resistance and Metabolic Disorder
Table 5
Effect of thiazolidin-4-ones on liver antioxidant enzyme and malondialdehyde level.
Liver biomarkers
NPD
HCD
Pioglitazone
Compound 2e
Compound 3a
GSH (nmole/mg of protein)
55.8 ± 2.1
46.4 ± 2.1a
63.2 ± 1.5b
68.3 ± 2.0b
67.8 ± 4.3b
CAT (U/mg of protein)
89.2 ± 5.7
55.4 ± 3.1a
93.8 ± 1.0b
81.9 ± 2.4b
87.5 ± 7.4b
SOD (U/mg of protein)
186.8 ± 23.2
108.1 ± 11.2a
174.8 ± 14.4b
202.2 ± 4.7b
208.0 ± 15.4b
GST (U/mg of protein)
0.43 ± 0.05
0.37 ± 0.01a
0.73 ± 0.02b
0.70 ± 0.01b
0.72 ± 0.04b
MDA (nmole/mg of protein)
0.57 ± 0.06
1.0 ± 0.33a
0.46 ± 0.01b
0.40 ± 0.01b
0.41 ± 0.02b
Represents as compared to NPD group (normal pellet diet).
bRepresents as compared to HCD group (high carbohydrate diet).